20 articles
Phase 1 trial examines whether vesatolimod can safely stimulate immune response in HIV controllers during treatment interruption.
Researchers develop standardized lung washing procedure that rapidly improves breathing and quality of life in patients with rare disease.
A Phase 4 trial compares two antiretroviral strategies in treatment-naive HIV patients with dangerously low CD4 counts below 100.
A German proof-of-concept trial tests whether a maximal five-class antiretroviral regimen can deplete latent HIV reservoirs.
A Phase 4 trial tests whether simplifying HIV treatment to two drugs worsens hidden viral replication and immune dysfunction.
65 neurologists from 54 Italian MS centers agree on when and how to use high-efficacy therapies to prevent irreversible disability.
A Phase II pilot trial tests whether adding carfilzomib to plasma exchange and IVIG can safely reverse antibody-mediated rejection after lung transplantation.
A Phase 3 trial compares neutralizing antibody responses from inactivated-virus vaccine VLA2001 vs. AZD1222, plus a dedicated adolescent arm.
A phase 1/2 trial finds low-dose oral NMN safely raises platelet counts in steroid-refractory ITP via a novel immunometabolic mechanism.
New research reveals gait retraining may improve overall posture and movement patterns, not just knee function.
A completed Phase II trial tested the checkpoint inhibitor ASC22 alongside antiretroviral therapy to target HIV-1 immune exhaustion.
Major study shows evolving therapies reduced lung disease progression from 21% to 12% in systemic sclerosis patients over the past decade.
A pilot study finds one 30-minute PAPIMI electromagnetic field session significantly reduced pain scores and raised parasympathetic HRV markers in chronic musculoskeletal pain patients.
BNT162b2 mRNA vaccine induces special immune cells that protect against severe illness and may slow aging-related decline.
Delphi study of 166 Italian neurologists establishes guidelines for individualized MS therapy based on patient needs and drug characteristics.
A Phase 1/2 trial evaluates a dual RSV/hMPV vaccine candidate in older adults, targeting two major respiratory threats with a single shot.
A blinded head-to-head comparison finds a fully automated single-copy RNA assay detects residual HIV in over 57% of suppressed patients, versus ≤40% for manual methods.
New research shows how targeted interleukin-2 treatment can restore regulatory T cells and reduce muscle inflammation in autoimmune conditions.
New research reveals mortality from this rare immune disorder varies by time, potentially improving treatment strategies.
Stanford researchers used modified immune proteins to enhance neurogenesis and cognitive function in aged mouse brains.
